GT201400222A - Agentes para tratar trastornos que implican la modulación de receptores de rianodina - Google Patents
Agentes para tratar trastornos que implican la modulación de receptores de rianodinaInfo
- Publication number
- GT201400222A GT201400222A GT201400222A GT201400222A GT201400222A GT 201400222 A GT201400222 A GT 201400222A GT 201400222 A GT201400222 A GT 201400222A GT 201400222 A GT201400222 A GT 201400222A GT 201400222 A GT201400222 A GT 201400222A
- Authority
- GT
- Guatemala
- Prior art keywords
- rianodine
- receptors
- involve
- modulation
- agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/36—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/841—Muscles; heart
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Hematology (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A DERIVADOS 1,4 BENZOTIAZEPINA Y A SU USO PARA TRATAR TRASTORNOS Y ENFERMEDADES ASOCIADAS CON LOS RECEPTORES DE RIANODINA (RYR) QUE REGULAN EL FUNCIONAMIENTO DEL CANAL DE CALCIO EN LAS CÉLULAS, LA INVENCIÓN TAMBIÉN DESCRIBE COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN ESTOS COMPUESTOS Y USOS DE ÉSTAS PARA TRATAR ENFERMEDADES Y AFECCIONES ASOCIADAS CON LOS RYR, EN PARTICULAR, TRASTORNOS CARDIACOS, MUSCULOESQUELÉTICOS Y DEL SISTEMA NERVIOSO CENTRAL (SNC).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261625890P | 2012-04-18 | 2012-04-18 | |
| EP12167732.2A EP2708535A1 (en) | 2012-05-11 | 2012-05-11 | Agents for treating disorders involving modulation of ryanodine receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT201400222A true GT201400222A (es) | 2018-09-28 |
Family
ID=49165460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT201400222A GT201400222A (es) | 2012-04-18 | 2014-10-17 | Agentes para tratar trastornos que implican la modulación de receptores de rianodina |
Country Status (48)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9725429B2 (en) | 2013-03-15 | 2017-08-08 | Rosalind Franklin University Of Medicine And Science | Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release |
| CN105209030B (zh) | 2013-03-15 | 2018-06-12 | 罗莎琳德富兰克林医科大学 | 用于稳定兰尼碱受体使其免于异常水平的钙释放的化合物 |
| AU2014290368B2 (en) | 2013-07-18 | 2019-07-11 | Baylor College Of Medicine | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia |
| WO2015197562A1 (en) * | 2014-06-23 | 2015-12-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of disorders or diseases associated with ryanodine receptor dysfunction |
| EP3176164B1 (en) | 2014-07-30 | 2019-08-21 | Aetas Pharma Co. Ltd. | Optical isomer of 1,4-benzothiazepine-1-oxide derivative, and pharmaceutical composition prepared using same |
| JP2018500382A (ja) * | 2014-12-30 | 2018-01-11 | マイオセリックス，インコーポレイティド | 新規カルシウム調節剤 |
| ES2643856B1 (es) * | 2016-05-24 | 2018-08-03 | Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea | Triazoles para la regulación de la homeostasis de calcio intracelular |
| WO2018165171A1 (en) | 2017-03-06 | 2018-09-13 | Washington University | Treatment for wolfram syndrome and other endoplasmic reticulum stress disorders |
| WO2019082940A1 (ja) * | 2017-10-25 | 2019-05-02 | 学校法人順天堂 | リアノジン受容体阻害薬 |
| JP7411315B2 (ja) | 2018-04-19 | 2024-01-11 | トゥヴァルディ セラピューティクス，インク． | Ｓｔａｔ３阻害剤 |
| US11026905B2 (en) | 2018-04-19 | 2021-06-08 | Tvardi Therapeutics, Inc. | STAT3 inhibitors |
| KR20220131947A (ko) | 2020-01-24 | 2022-09-29 | 트발디 테라퓨틱스, 인크. | 치료 화합물, 제제 및 이의 용도 |
| AR124008A1 (es) * | 2020-11-06 | 2023-02-01 | Cytokinetics Inc | 1,4-diazepanonas bicíclicas y sus usos terapéuticos |
| EP4274580A1 (en) | 2021-01-08 | 2023-11-15 | Armgo Pharma, Inc. | Crystalline forms of a ryanodine receptor modulator and uses thereof |
| US11717526B2 (en) | 2021-05-20 | 2023-08-08 | Armgo Pharma, Inc. | Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof |
| WO2023091524A1 (en) * | 2021-11-16 | 2023-05-25 | Armgo Pharma, Inc. | Therapeutic compounds |
| EP4230196A1 (en) | 2022-02-21 | 2023-08-23 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of dystrophinopathies |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0368063B1 (de) * | 1988-11-05 | 1992-06-10 | Bayer Ag | Verfahren zur Kernchlorierung von aromatischen Kohlenwasserstoffen |
| GB9021813D0 (en) * | 1990-10-08 | 1990-11-21 | Ici Plc | Tricyclic heterocycles |
| JP3497164B2 (ja) | 1991-06-28 | 2004-02-16 | スミスクライン・ビーチャム・コーポレイション | 二環式フィブリノーゲン拮抗薬 |
| US5580866A (en) * | 1992-11-09 | 1996-12-03 | The Boots Company Plc | Therapeutic 1,4-thiazepines |
| FR2752017B1 (fr) | 1996-08-01 | 1998-10-16 | Hispano Suiza Sa | Inverseur de poussee de turboreacteur a portes formant ecopes |
| GB9914745D0 (en) | 1999-06-24 | 1999-08-25 | Knoll Ag | Therapeutic agents |
| US7879840B2 (en) * | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US7718644B2 (en) | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
| US8022058B2 (en) * | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US20040229781A1 (en) * | 2000-05-10 | 2004-11-18 | Marks Andrew Robert | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
| US20020183307A1 (en) | 2000-07-26 | 2002-12-05 | Tremont Samuel J. | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake |
| KR100820598B1 (ko) | 2000-10-30 | 2008-04-08 | 얀센 파마슈티카 엔.브이. | 트리펩티딜 펩티다아제 저해제 |
| US7544678B2 (en) | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
| WO2004080283A2 (en) | 2003-03-07 | 2004-09-23 | The Trustees Of Columbia University, In The City Of New York | Type 1 ryanodine receptor-based methods |
| US20090292119A1 (en) * | 2003-10-07 | 2009-11-26 | The Trustees Of Columbia University In The City Of New York | Methods for synthesizing benzothiazepine compounds |
| DE112005003511T5 (de) | 2005-03-23 | 2008-04-17 | Battelle Memorial Institute, Richland | RFID-System mit verbesserter Leistungsfähigkeit |
| US7704990B2 (en) | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| WO2007127145A2 (en) | 2006-04-25 | 2007-11-08 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for treatment of cardiac arrhythmia in non-human animals |
| WO2008060332A2 (en) | 2006-06-02 | 2008-05-22 | The Trustees Of Columbia University In The City Of New York | Methods for treating or reducing muscle fatigue |
| WO2008021432A2 (en) | 2006-08-17 | 2008-02-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treatment of conditions affecting the nervous system |
| WO2008021439A2 (en) * | 2006-08-17 | 2008-02-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treatment of cardiac hypertrophy |
| WO2008064264A2 (en) | 2006-11-20 | 2008-05-29 | Armgo Pharma, Inc. | In vivo methods for identifying and screening compounds that modulate calstabin binding to a ryanodine receptor |
| EP2250159B1 (en) | 2008-03-03 | 2011-12-07 | Armgo Pharma, Inc. | Process for preparing benzothiazepines from gamma-aminoalkylbenzenes |
| CN101891706B (zh) * | 2010-04-09 | 2013-05-29 | 复旦大学 | 3,4-二氢苯并[f][1,4]噻氮杂*类化合物或其盐及其药物用途 |
| WO2012019076A1 (en) | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for preventing and treating cardiac ischemia/reperfusion injury |
| WO2012019071A1 (en) | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Methods of preventing and treating sarcopenia |
| WO2012037105A1 (en) | 2010-09-14 | 2012-03-22 | The Trustees Of Columbia University In The City Of New York | Methods of treating, ameliorating or preventing stress-induced neuronal disorders and diseases |
-
2012
- 2012-05-11 EP EP12167732.2A patent/EP2708535A1/en not_active Withdrawn
-
2013
- 2013-04-09 JO JOP/2013/0090A patent/JO3070B1/ar active
- 2013-04-12 UY UY0001034742A patent/UY34742A/es not_active Application Discontinuation
- 2013-04-17 CN CN201380030477.8A patent/CN104350045B/zh active Active
- 2013-04-17 MX MX2014012575A patent/MX350890B/es active IP Right Grant
- 2013-04-17 SA SA113340479A patent/SA113340479B1/ar unknown
- 2013-04-17 PT PT131640518T patent/PT2653466E/pt unknown
- 2013-04-17 AU AU2013248313A patent/AU2013248313B2/en active Active
- 2013-04-17 EP EP20130164051 patent/EP2653466B1/en active Active
- 2013-04-17 TW TW102113668A patent/TWI507399B/zh active
- 2013-04-17 NZ NZ701122A patent/NZ701122A/en unknown
- 2013-04-17 MD MDA20140119A patent/MD4489C1/ro not_active IP Right Cessation
- 2013-04-17 ME MEP-2014-147A patent/ME01969B/me unknown
- 2013-04-17 WO PCT/EP2013/057958 patent/WO2013156505A1/en active Application Filing
- 2013-04-17 CU CUP2014000119A patent/CU24327B1/es unknown
- 2013-04-17 ES ES13164051.8T patent/ES2529890T3/es active Active
- 2013-04-17 MY MYPI2014702980A patent/MY167783A/en unknown
- 2013-04-17 JP JP2015506221A patent/JP5965542B2/ja active Active
- 2013-04-17 PL PL13164051T patent/PL2653466T3/pl unknown
- 2013-04-17 AR ARP130101246A patent/AR090712A1/es unknown
- 2013-04-17 BR BR112014025670-5A patent/BR112014025670B1/pt active IP Right Grant
- 2013-04-17 HU HUE13164051A patent/HUE024284T2/en unknown
- 2013-04-17 SI SI201330014T patent/SI2653466T1/sl unknown
- 2013-04-17 UA UAA201412301A patent/UA113759C2/uk unknown
- 2013-04-17 CA CA2870599A patent/CA2870599C/en active Active
- 2013-04-17 SG SG11201406404YA patent/SG11201406404YA/en unknown
- 2013-04-17 RS RS20140701A patent/RS53711B1/en unknown
- 2013-04-17 RU RU2014145939A patent/RU2644350C2/ru not_active IP Right Cessation
- 2013-04-17 KR KR1020147032345A patent/KR101731459B1/ko active IP Right Grant
- 2013-04-17 DK DK13164051.8T patent/DK2653466T3/en active
- 2013-04-17 AP AP2014008011A patent/AP3591A/xx active
- 2013-04-17 EA EA201401141A patent/EA027922B1/ru not_active IP Right Cessation
- 2013-04-17 PE PE2014001612A patent/PE20142193A1/es active IP Right Grant
- 2013-04-18 US US13/865,359 patent/US20130281512A1/en not_active Abandoned
- 2013-11-11 US US14/076,474 patent/US8853198B2/en active Active
-
2014
- 2014-04-22 HK HK14103808.0A patent/HK1192537A1/zh unknown
- 2014-09-03 US US14/475,980 patent/US20140378437A1/en not_active Abandoned
- 2014-10-07 IL IL235043A patent/IL235043A/en active IP Right Grant
- 2014-10-07 PH PH12014502256A patent/PH12014502256B1/en unknown
- 2014-10-10 TN TN2014000424A patent/TN2014000424A1/fr unknown
- 2014-10-10 CO CO14224913A patent/CO7091184A2/es active IP Right Grant
- 2014-10-13 DO DO2014000230A patent/DOP2014000230A/es unknown
- 2014-10-14 CL CL2014002756A patent/CL2014002756A1/es unknown
- 2014-10-14 CR CR20140476A patent/CR20140476A/es unknown
- 2014-10-15 ZA ZA2014/07499A patent/ZA201407499B/en unknown
- 2014-10-17 GT GT201400222A patent/GT201400222A/es unknown
- 2014-10-30 NI NI201400123A patent/NI201400123A/es unknown
- 2014-11-13 MA MA37525A patent/MA37525B1/fr unknown
- 2014-11-17 EC ECIEPI201427564A patent/ECSP14027564A/es unknown
- 2014-11-18 HR HRP20141113TT patent/HRP20141113T8/hr unknown
- 2014-12-17 CY CY20141101052T patent/CY1115826T1/el unknown
-
2015
- 2015-08-10 HK HK15107691.0A patent/HK1207073A1/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201400222A (es) | Agentes para tratar trastornos que implican la modulación de receptores de rianodina | |
| GT201600233A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| UY37124A (es) | Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos | |
| ECSP14017269A (es) | Compuestos para tratar la atrofia muscular espinal | |
| CR20180336A (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
| UY35427A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
| SV2015005066A (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
| UY35425A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
| DOP2015000246A (es) | Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares | |
| UY35426A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
| CO2018005315A2 (es) | Moduladores de la interacción de sestrina-gator2 y sus usos | |
| CU24603B1 (es) | Imidazopirimidinas diazabicíclicas sustituidas útiles en el tratamiento de trastornos respiratorios | |
| UY35472A (es) | Compuestos y sus usos en la modulacion de la hemoglobina | |
| UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
| ECSP12011720A (es) | Compuestos heterocíclicos y usos de los mismos | |
| PE20151416A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos | |
| UY32937A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119 | |
| UY37947A (es) | Amidas de imidazopiridina sustituidas y su uso | |
| CR20150248A (es) | Derivados de oxazolidin-2-ona-pirimidina | |
| DOP2016000170A (es) | Compuestos derivados de hidroxiformamida y usos del mismo | |
| CL2017000827A1 (es) | Inhibidores de aldosterona sintasa | |
| UY34991A (es) | Inhibidores de la beta-secretasa | |
| CL2020000127A1 (es) | Moduladores terapéuticos del modo inverso de la atp sintasa. | |
| BR112016019893A2 (pt) | composições de glicoproteína sialilada e seus usos |